Serum IgE against galactose-alpha-1,3-galactose is common in Laotian patients with snakebite envenoming but not the major trigger for early anaphylactic reactions to antivenom.
Anaphylaxis
Galactose-alpha-1,3-galactose
Laos
Snake antivenom
Snakebite
Journal
Toxicon: X
ISSN: 2590-1710
Titre abrégé: Toxicon X
Pays: England
ID NLM: 101741983
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
25
05
2020
revised:
30
06
2020
accepted:
22
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Snake antivenom is the only specific treatment for snakebite envenoming, but life-threatening anaphylaxis is a severe side effect and drawback for the use of these typically mammalian serum products. The present study investigates the hypotheses whether serum IgE antibodies against the epitope galactose-alpha-1,3-galactose (α-gal) located on the heavy chain of non-primate mammalian antibodies are a possible cause for hypersensitivity reactions to snake antivenom. Serum samples from 55 patients with snakebite envenoming were obtained before administration of snake antivenom and tested for serum IgE (sIgE) against α-gal and total IgE. Early anaphylactic reactions (EARs) during the first 3 h after antivenom administration were classified into mild, moderate or severe and correlated with the presence of sIgE against α-gal. Fifteen (27%) out of 55 patients (37 male, 18 female, median 34 years, range 9-90 years) developed EARs after antivenom administration. Eleven, three and one patients had mild, moderate and severe EARs, respectively. Serum IgE against α-gal was detected in 17 patients (31%); in five (33%) out of 15 patients with EARs and in 12 (30%) out of 40 patients without EAR (Odds Ratio = 1.2; 95%-confidence interval: 0.3-4.2) with no correlation to severity. Although the prevalence of serum IgE against α-gal was high in the study population, very high levels of total IgE in the majority of patients question their clinical relevance and rather indicate unspecific sIgE binding instead of allergy. Lack of correlation between α-gal sIgE and EARs together with significantly increased total IgE levels suggest that sIgE against α-gal is not the major trigger for hypersensitivity reactions against snake antivenom.
Identifiants
pubmed: 32776003
doi: 10.1016/j.toxcx.2020.100054
pii: S2590-1710(20)30032-1
pii: 100054
pmc: PMC7393571
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100054Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
PLoS Negl Trop Dis. 2013 Jul 25;7(7):e2326
pubmed: 23936562
Pediatr Allergy Immunol. 2018 Dec;29(8):841-849
pubmed: 30144162
Br J Clin Pharmacol. 2016 Mar;81(3):446-52
pubmed: 26256124
PLoS Negl Trop Dis. 2011 Apr 12;5(4):e1037
pubmed: 21532735
J Allergy Clin Immunol. 2015 Mar;135(3):589-96; quiz 597
pubmed: 25747720
Ann Allergy Asthma Immunol. 2014 Feb;112(2):97-101
pubmed: 24468247
Toxicon. 2013 Dec 15;76:63-76
pubmed: 24055551
J Allergy Clin Immunol. 2004 Aug;114(2):371-6
pubmed: 15316518
Allergy. 2017 Oct;72(10):1540-1547
pubmed: 28273338
Toxicon. 2016 Jul;117:13-21
pubmed: 26995210
Clin Exp Allergy. 2014 Aug;44(8):1061-8
pubmed: 24750173
Acta Trop. 2008 Feb;105(2):203-5
pubmed: 17996842
Lancet Glob Health. 2013 Jul;1(1):e46-54
pubmed: 24748368
N Engl J Med. 2008 Mar 13;358(11):1109-17
pubmed: 18337601
Allergy. 2017 May;72(5):764-771
pubmed: 27775867
Allergo J Int. 2016;25:55-62
pubmed: 27226951
J Allergy Clin Immunol. 2011 May;127(5):1286-93.e6
pubmed: 21453959